The report "Rosacea - Pipeline Review, H1 2016" market research report provides complete comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rosacea and special features on late-stage and discontinued projects.
The report also reviews key players involved in the therapeutic development for Rosacea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Companies discussed in this Rosacea Pipeline Review, H1 2016 report include Allergan Plc, Amorepacific Corporation, Delenex Therapeutics AG, Foamix Pharmaceuticals Ltd., Hovione FarmaCiencia SA, Merz Pharma GmbH & Co. KgaA, Promius Pharma, LLC, TWi Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, Inc.Drug profiles discussed in this research report are AC-701, ACUD-1, DLX-1008, DMT-200, DMT-210, DMT-220, FMX-103, incobotulinumtoxin A, itraconazole, minocycline, omiganan pentahydrochloride, oxymetazoline hydrochloride, PAC-14028, DI-320 and tetracycline MR.
The report provides a snapshot of the global therapeutic landscape of Rosacea and reviews pipeline therapeutics for Rosacea by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Rosacea therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Rosacea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Rosacea.
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Rosacea
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Rosacea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Please find more about Rosacea - Pipeline Review, H1 2016 at reports.zursh.com
Click on below items to see free updates about the topic covered.
Click on below items to see free resources and reports about the topic covered.